Analyst Price Target is $20.80
▲ +68.42% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lexeo Therapeutics in the last 3 months. The average price target is $20.80, with a high forecast of $23.00 and a low forecast of $19.00. The average price target represents a 68.42% upside from the last price of $12.35.
Current Consensus is
Buy
The current consensus among 6 polled investment analysts is to buy stock in Lexeo Therapeutics. This Buy consensus rating has held steady for over two years.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More